MY194364A - Polymorphic Forms of Kinase Inhibitor Compound, Pharmaceutical Composition Containing Same, Preparation Method Therefor and use Thereof - Google Patents
Polymorphic Forms of Kinase Inhibitor Compound, Pharmaceutical Composition Containing Same, Preparation Method Therefor and use ThereofInfo
- Publication number
- MY194364A MY194364A MYPI2019000596A MYPI2019000596A MY194364A MY 194364 A MY194364 A MY 194364A MY PI2019000596 A MYPI2019000596 A MY PI2019000596A MY PI2019000596 A MYPI2019000596 A MY PI2019000596A MY 194364 A MY194364 A MY 194364A
- Authority
- MY
- Malaysia
- Prior art keywords
- crystalline form
- preparation
- formula
- method therefor
- containing same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610866253 | 2016-09-29 | ||
| PCT/CN2017/104506 WO2018059556A1 (zh) | 2016-09-29 | 2017-09-29 | 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY194364A true MY194364A (en) | 2022-11-29 |
Family
ID=61763329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019000596A MY194364A (en) | 2016-09-29 | 2017-09-29 | Polymorphic Forms of Kinase Inhibitor Compound, Pharmaceutical Composition Containing Same, Preparation Method Therefor and use Thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11053224B2 (enExample) |
| EP (1) | EP3502105B8 (enExample) |
| JP (2) | JP7253491B2 (enExample) |
| KR (1) | KR102289684B1 (enExample) |
| CN (1) | CN108884080B (enExample) |
| AU (1) | AU2017336889B2 (enExample) |
| CA (2) | CA3035124C (enExample) |
| EA (1) | EA201990688A1 (enExample) |
| ES (1) | ES2914294T3 (enExample) |
| IL (2) | IL265266B2 (enExample) |
| MY (1) | MY194364A (enExample) |
| PH (1) | PH12019500681A1 (enExample) |
| PL (1) | PL3502105T3 (enExample) |
| SG (1) | SG11201901962QA (enExample) |
| TW (1) | TWI647224B (enExample) |
| WO (1) | WO2018059556A1 (enExample) |
| ZA (1) | ZA201901717B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201901962QA (en) * | 2016-09-29 | 2019-04-29 | Equinox Sciences Llc | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| CA3171563A1 (en) | 2020-03-25 | 2021-09-30 | Charles D. Blizzard | Ocular implant containing a tyrosine kinase inhibitor |
| SI4210682T1 (sl) | 2020-09-14 | 2026-07-31 | EyePoint, Inc. | Bioerozibilni očesni vložek za dovajanje zdravil in terapevtska metoda |
| CN117157294A (zh) * | 2021-03-16 | 2023-12-01 | 怡诺安有限公司 | 作为蛋白激酶抑制剂的杂环化合物的结晶形式 |
| JP7138982B1 (ja) | 2021-09-24 | 2022-09-20 | 東海物産株式会社 | アンセリンの結晶及びその製造方法 |
| IL315331A (en) | 2022-03-11 | 2024-10-01 | Eyepoint Pharmaceuticals Inc | A method of preventing age-related ocular degeneration by providing a drug entry mechanism into the eye |
| US20250186398A1 (en) | 2022-03-11 | 2025-06-12 | EyePoint Pharmaceuticals, Inc. | Continuous dosing regimen for treatment of a condition of the eye |
| TW202345804A (zh) | 2022-03-11 | 2023-12-01 | 美商視點製藥有限公司 | 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法 |
| JP2026520094A (ja) | 2023-04-11 | 2026-06-22 | オキュラ セラピューティクス，インコーポレイテッド | アキシチニブ多形ｉｖを含む眼科インプラント |
| CN117143083B (zh) * | 2023-08-30 | 2026-02-27 | 沈阳药科大学 | VEGFR抑制剂Vorolanib的合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005508953A (ja) * | 2001-10-10 | 2005-04-07 | スージェン・インコーポレーテッド | キナーゼ阻害剤としての３−［４−（置換ヘテロサイクリル）−ピロール−２−イルメチリデン］−２−インドリノン誘導体 |
| WO2008033562A2 (en) * | 2006-09-15 | 2008-03-20 | Xcovery, Inc. | Kinase inhibitor compounds |
| US20110026367A1 (en) * | 2007-05-07 | 2011-02-03 | Baumer Electric Ag | Acoustic Transducer |
| US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
| WO2009128083A1 (en) * | 2008-04-16 | 2009-10-22 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
| CN102066362B (zh) | 2008-05-23 | 2014-07-30 | 上海医药工业研究院 | 二氢吲哚酮衍生物 |
| EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
| EP2264027A1 (en) | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| CN106928114B (zh) * | 2015-12-31 | 2020-07-28 | 韶远科技（上海)有限公司 | 含有脲基的环状手性氨基类化合物及其可放大工艺和用途 |
| SG11201901962QA (en) * | 2016-09-29 | 2019-04-29 | Equinox Sciences Llc | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof |
-
2017
- 2017-09-29 SG SG11201901962QA patent/SG11201901962QA/en unknown
- 2017-09-29 WO PCT/CN2017/104506 patent/WO2018059556A1/zh not_active Ceased
- 2017-09-29 KR KR1020197008752A patent/KR102289684B1/ko active Active
- 2017-09-29 CN CN201780008042.1A patent/CN108884080B/zh active Active
- 2017-09-29 US US16/338,357 patent/US11053224B2/en active Active
- 2017-09-29 IL IL265266A patent/IL265266B2/en unknown
- 2017-09-29 CA CA3035124A patent/CA3035124C/en active Active
- 2017-09-29 PL PL17855006T patent/PL3502105T3/pl unknown
- 2017-09-29 EP EP17855006.7A patent/EP3502105B8/en active Active
- 2017-09-29 TW TW106133830A patent/TWI647224B/zh active
- 2017-09-29 MY MYPI2019000596A patent/MY194364A/en unknown
- 2017-09-29 CA CA3253105A patent/CA3253105A1/en active Pending
- 2017-09-29 AU AU2017336889A patent/AU2017336889B2/en active Active
- 2017-09-29 EA EA201990688A patent/EA201990688A1/ru unknown
- 2017-09-29 JP JP2019538551A patent/JP7253491B2/ja active Active
- 2017-09-29 ES ES17855006T patent/ES2914294T3/es active Active
-
2019
- 2019-03-19 ZA ZA201901717A patent/ZA201901717B/en unknown
- 2019-03-28 PH PH12019500681A patent/PH12019500681A1/en unknown
-
2021
- 2021-06-15 US US17/348,482 patent/US12209080B2/en active Active
-
2023
- 2023-03-28 JP JP2023052465A patent/JP7763203B2/ja active Active
-
2024
- 2024-03-20 IL IL311631A patent/IL311631B2/en unknown
-
2025
- 2025-01-27 US US19/038,129 patent/US20250188063A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901962QA (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
| MX2021006283A (es) | Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos. | |
| PH12017502331A1 (en) | 1,4-substituted piperidine derivatives | |
| ZA201805185B (en) | Tlr7 agonist maleate salt, crystalline forms c, d and e thereof, preparation methods and uses of maleate salt and crystalline forms | |
| PH12017501478A1 (en) | 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists | |
| WO2017175068A8 (en) | Thiazolopyridine derivatives as gpr119 agonists | |
| MY210123A (en) | Tlr7/8 antagonists and uses thereof | |
| TN2018000410A1 (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| MY186830A (en) | A novel carystalline from of a benzimidazole derivative and a preparation method thereof | |
| WO2016105564A8 (en) | Quinazoline derivatives used to treat hiv | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2021000093A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. | |
| TN2018000395A1 (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| NZ716840A (en) | Combination formulation of two antiviral compounds | |
| PH12015502802A1 (en) | Formulation comprising a hypolipidemic agent | |
| MX391538B (es) | Proceso de compuesto antifungico. | |
| PH12021551873A1 (en) | Hydroxypyridoxazepines as nrf2 activators | |
| WO2013177534A3 (en) | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | |
| MX2016005993A (es) | Anfifilos biscationicos y triscationicos como agentes antimicrobianos. | |
| MX2016004963A (es) | Sal y formas cristalinas de inhibidores de quinasa tipo polo-4. | |
| PH12019500822A1 (en) | Crystalline forms of eravacycline | |
| SA521430909B1 (ar) | B تركيبة علف تتضمن مركب سداسي هيدرو حامضى ومركبات وتطبيق منها | |
| MX2020006370A (es) | Pirazolopiridina-diamidas, su uso como insecticida y procesos para prepararlas. | |
| MA39715A (fr) | Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation |